Dermtech Stock Gross Profit
DermTech fundamentals help investors to digest information that contributes to DermTech's financial success or failures. It also enables traders to predict the movement of DermTech Stock. The fundamental analysis module provides a way to measure DermTech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to DermTech stock.
DermTech |
DermTech Company Gross Profit Analysis
DermTech's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Current DermTech Gross Profit | 647 K |
Most of DermTech's fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, DermTech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
CompetitionAccording to the company disclosure, DermTech reported 647 K of gross profit. This is 99.97% lower than that of the Biotechnology sector and 99.93% lower than that of the Health Care industry. The gross profit for all United States stocks is 100.0% higher than that of the company.
DermTech Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DermTech's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DermTech could also be used in its relative valuation, which is a method of valuing DermTech by comparing valuation metrics of similar companies.DermTech is currently under evaluation in gross profit category among its peers.
DermTech Fundamentals
| Return On Equity | -1.22 | |||
| Return On Asset | -0.39 | |||
| Operating Margin | (5.33) % | |||
| Current Valuation | 15.43 M | |||
| Shares Outstanding | 34.96 M | |||
| Shares Owned By Insiders | 2.62 % | |||
| Shares Owned By Institutions | 18.09 % | |||
| Number Of Shares Shorted | 3.36 M | |||
| Price To Earning | (139.70) X | |||
| Price To Book | 0.02 X | |||
| Price To Sales | 0.21 X | |||
| Revenue | 15.3 M | |||
| Gross Profit | 647 K | |||
| EBITDA | (97.89 M) | |||
| Net Income | (100.89 M) | |||
| Cash And Equivalents | 173.79 M | |||
| Cash Per Share | 5.78 X | |||
| Total Debt | 54.39 M | |||
| Debt To Equity | 0.14 % | |||
| Current Ratio | 12.19 X | |||
| Book Value Per Share | 1.14 X | |||
| Cash Flow From Operations | (76.98 M) | |||
| Short Ratio | 2.64 X | |||
| Earnings Per Share | (2.65) X | |||
| Target Price | 1.5 | |||
| Number Of Employees | 206 | |||
| Beta | 2.42 | |||
| Market Capitalization | 3.29 M | |||
| Total Asset | 121.93 M | |||
| Retained Earnings | (423.94 M) | |||
| Working Capital | 48.3 M | |||
| Current Asset | 140.61 K | |||
| Current Liabilities | 446.54 K | |||
| Net Asset | 121.93 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Other Consideration for investing in DermTech Stock
If you are still planning to invest in DermTech check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the DermTech's history and understand the potential risks before investing.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |